The market for Addison’s disease (primary adrenal insufficiency) therapeutics is small but steadily expanding as diagnosis improves, supply chains mature, and patient-centric formulations gain traction. While estimates vary, most analysts project mid-single to low-double-digit growth through the decade as glucocorticoid and mineralocorticoid replacement remain standard of care and new...